Pages that link to "Q50001757"
Jump to navigation
Jump to search
The following pages link to TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. (Q50001757):
Displaying 50 items.
- Contextual determinants of TGFβ action in development, immunity and cancer. (Q52593116) (← links)
- Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors? (Q52621246) (← links)
- Regulation and Function of the PD-L1 Checkpoint. (Q52725238) (← links)
- Bladder cancer: Mechanisms of anti-PDL1 resistance. (Q53704341) (← links)
- Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? (Q55240544) (← links)
- Fibroblasts in the Tumor Microenvironment: Shield or Spear? (Q55324986) (← links)
- Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. (Q55380684) (← links)
- Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. (Q55411157) (← links)
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. (Q55491725) (← links)
- TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. (Q55515390) (← links)
- The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer (Q56529776) (← links)
- Mechanisms of Resistance to Immune Checkpoint Blockade (Q56886821) (← links)
- Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF-β Inhibitor Sequencing in Melanoma (Q56888926) (← links)
- Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer (Q56889941) (← links)
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response (Q56895003) (← links)
- Roles of the immune system in cancer: from tumor initiation to metastatic progression (Q57055334) (← links)
- The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer (Q57066369) (← links)
- Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway (Q57116103) (← links)
- Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance (Q57167969) (← links)
- Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences (Q57191808) (← links)
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) (Q57295962) (← links)
- Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity (Q57296955) (← links)
- The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity (Q57789211) (← links)
- Immune regulation of metastasis: mechanistic insights and therapeutic opportunities (Q57791068) (← links)
- Post-translational modifications in bladder cancer: Expanding the tumor target repertoire (Q57813952) (← links)
- Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again (Q58087985) (← links)
- Role of the immunosuppressive microenvironment in immunotherapy (Q58119186) (← links)
- Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells (Q58599390) (← links)
- Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic (Q58609277) (← links)
- A Festschrift in Honor of Edward M. Messing, MD, FACS (Q58691149) (← links)
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer (Q58695604) (← links)
- A Paradoxical Correlation of Cancer-Associated Fibroblasts With Survival Outcomes in B-Cell Lymphomas and Carcinomas (Q58698491) (← links)
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors (Q58713932) (← links)
- Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies (Q58724935) (← links)
- Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer (Q58725140) (← links)
- TGF-β Signaling in Lung Health and Disease (Q58734182) (← links)
- Radiation and Local Anti-CD40 Generate an Effective Vaccine in Preclinical Models of Pancreatic Cancer (Q58758908) (← links)
- Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment (Q58773649) (← links)
- Tissue-Specific Roles of NKT Cells in Tumor Immunity (Q58777562) (← links)
- Single-cell reconstruction of the early maternal–fetal interface in humans (Q59068540) (← links)
- Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology (Q59129137) (← links)
- Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer (Q59129654) (← links)
- The evolving relationship of wound healing and tumor stroma (Q59134962) (← links)
- Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors (Q59327125) (← links)
- Please stand by: how oncolytic viruses impact bystander cells (Q59351336) (← links)
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer (Q59356808) (← links)
- PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer (Q59357945) (← links)
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations (Q59793953) (← links)
- SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art (Q59793957) (← links)
- Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC (Q59798144) (← links)